Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
Public ClinicalTrials.gov record NCT00003634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind Placebo Controlled Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Ovarian Tubal and Peritoneal Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether giving monoclonal antibody therapy is more effective than a placebo in treating patients with ovarian epithelial, fallopian tube, or peritoneal cancer who have responded to surgery and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients with residual disease from stage III or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer following surgery and chemotherapy.
Study identification
- NCT ID
- NCT00003634
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 400 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1998 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Nov 6, 2013
Started 1998
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033-0800 | — |
| Jonsson Comprehensive Cancer Center, UCLA | Los Angeles | California | 90095-1781 | — |
| Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Wilshire Oncology Medical Center | Pomona | California | 91767 | — |
| Stanford University School of Medicine | Stanford | California | 94305-5317 | — |
| University of Colorado Cancer Center | Denver | Colorado | 80262 | — |
| Patty Berg Cancer Center | Fort Myers | Florida | 33901 | — |
| University of Florida Health Science Center - Jacksonville | Jacksonville | Florida | 32209 | — |
| Walt Disney Memorial Cancer Institute | Orlando | Florida | 32804 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637 | — |
| Saint Mary's Hospital | East Saint Louis | Illinois | 62201 | — |
| Lutheran General Cancer Care Center | Park Ridge | Illinois | 60068 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Alton Ochsner Medical Foundation Hospital | New Orleans | Louisiana | 70121 | — |
| Marlene & Stewart Greenebaum Cancer Center, University of Maryland | Baltimore | Maryland | 21201 | — |
| New England Medical Center Hospital | Boston | Massachusetts | 02111 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| University of Minnesota Medical School | Minneapolis | Minnesota | 55455 | — |
| Ellis Fischel Cancer Center | Columbia | Missouri | 65203 | — |
| North Shore University Hospital | Manhasset | New York | 11030 | — |
| State University of New York - Upstate Medical University | Syracuse | New York | 13210 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73190 | — |
| Spartanburg Regional Medical Center | Spartanburg | South Carolina | 29303 | — |
| Baptist Regional Cancer Center - Knoxville | Knoxville | Tennessee | 37901 | — |
| University of Texas Southwestern Medical School | Dallas | Texas | 75235-9032 | — |
| U.S. Oncology | Houston | Texas | 77060 | — |
| Cancer Center, University of Virginia HSC | Charlottesville | Virginia | 22908 | — |
| Swedish Hospital Tumor Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2013 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00003634 live on ClinicalTrials.gov.